Who we are
TIB MOLBIOL® – Fast. Precise. Flexible.
We develop reliable real-time PCR based tests at high speed and ensure that laboratories and patients get the answers they need – without fuss or frills, just in true Berlin style.
At TIB MOLBIOL, molecular diagnostics isn’t just what we do – it’s what we’ve been refining for over 35 years. We develop, manufacture, and supply Real-Time PCR kits, primer/probe sets, and key components used in medical diagnostics, research, and industrial manufacturing worldwide.
Founded in Berlin in 1990 and part of the Roche family since 2021, we combine the agility of a biotech pioneer with the reach of a global healthcare leader. Inside Roche, we’re known as the “speedboat” – developing high-quality molecular diagnostic assays for platforms like cobas® 5800/6800/8800, LightCycler® Pro, and Digital LightCycler®.
When new challenges emerge, our team acts fast. With a proven track record of rapid response, we’ve developed and delivered molecular diagnostic solutions for global outbreaks within weeks - helping labs and hospitals stay ahead when timing is critical.
Our approach is simple: science first, no fuss, no overcomplication. Just fast, precise, and flexible molecular diagnostics that labs can rely on every day.
We and Roche
TIB MOLBIOL is part of the Roche family since 2021. As a subsidiary of the Roche Group, we continue to see ourselves as a driver of innovation in the research and development of diagnostic solutions in the fight against diseases.
The acquisition significantly expands Roche’s portfolio, which includes over 70 CE-IVD assays and more than 250 research-use-only assays for the LightCycler® and cobas® PCR systems, by incorporating our extensive range of molecular diagnostics, including tests for SARS-CoV-2 variants. With our assays now available on Roche’s LightCycler®, the collaboration builds on a 20-year partnership that has enabled rapid responses to biological threats such as SARS, anthrax, H5N1, MERS, H1N1, Ebola, Zika, and SARS-CoV-2.
Together with Roche, we achieved a significant milestone in January 2020 by launching the first research test for SARS-CoV-2, merely days after the virus's genetic sequence was made available. This swift development underscored our shared commitment to addressing emergent public health threats with urgency and precision. Through our partnership, we have established the broadest portfolio of PCR-based tests available on the market, encompassing a wide range of diagnostic solutions. This extensive portfolio not only highlights our innovative prowess but also ensures that healthcare providers globally have access to reliable and versatile testing options to manage and mitigate the spread of infectious diseases effectively.
Our DNA
is all about developing reliable real-time PCR based tests at high speed and ensuring that laboratories and patients get the answers they need - without fuss or frippery, just the Berlin way. In doing so, we value close customer relationships and teamwork with local scientific experts.
Our Vision
is to continue to be the first responder to new infectious disease outbreaks, ensuring rapid, scalable, and automated diagnostic solutions are accessible worldwide. Renowned for our exceptional speed in developing assays for emerging infectious diseases, we have consistently demonstrated the expertise and agility necessary to respond to urgent public health threats. We will continue to expand our product portfolio for platforms like LightCycler®, cobas® and Digital LightCycler®. We are also committed to enabling medical research as a supplier for scalable custom oligonucleotides and tailor made PCR kits.
How it all
began
Founded in 1990, the company began with a focus on custom synthesis of oligonucleotides, a critical component in a variety of applications. Initially specializing in producing these short DNA or RNA sequences for specific customer needs, our oligonucleotides have been instrumental in supporting basic scientific research, environmental analysis, and quality control across diverse industries. Over time, our expertise expanded to include vital applications in medical diagnostics, where these oligonucleotides play a key role in detecting genetic mutations, pathogens, and other biomarkers, helping advance both research and clinical practices.
